ReviewBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz2022
[Epidemiology of viral hepatitis A to E in Germany].
Review in Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Self-reported hepatitis B diagnoses and vaccination history in trans and non-binary communities in Germany, the TASG-study* 2022.BMC public health · 2026Article
- Genetic variability of hepatitis A virus genotype I strains in Bulgaria, 2011-2023.BMC infectious diseases · 2026Article
- National trends in acute viral hepatitis in China from 1990-2023: An analysis of the Global Burden of Disease 2023 update.Chinese medical journal · 2026Article
- Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses.Biological procedures online · 2025Review
- Characterising HIV-Indicator conditions among two nationwide long-term cohorts of people living with HIV in Germany (1999-2023).Infection · 2025Observational
- Article
- [Surgery in ophthalmology during pregnancy].Die Ophthalmologie · 2025Article
- Feasibility of data extraction and evaluation with BeoNet-Halle: outcomes and data quality in hepatitis B and C screenings.Frontiers in medicine · 2025Article
- [Ferroptosis and liver diseases].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024Review
- Factors Positively Correlated with Hepatitis B Surface Antigen Seroconversion in Chronic Hepatitis B.Journal of personalized medicine · 2024Article
- Assessment of the Diagnostic Performance of Fully Automated Hepatitis E Virus (HEV) Antibody Tests.Diagnostics (Basel, Switzerland) · 2024Article
- Trends and projections of Hepatitis A incidence in eastern China from 2007 to 2021: an age-period-cohort analysis.Frontiers in public health · 2024Article
- Long-Term Treatment with Bulevirtide in Patients with Chronic Hepatitis D and Advanced Chronic Liver Disease.Canadian journal of gastroenterology & hepatology · 2024Article
- [(Rare) infectious hepatitis as an important differential diagnosis of unclear hepatopathy].Pathologie (Heidelberg, Germany) · 2023Article
- Sex differences in hepatitis A incidence rates-a multi-year pooled-analysis based on national data from nine high-income countries.PloS one · 2023Article
- Comparative Analysis on Clinical Characteristics Among Patients with Acute Hepatitis A Virus (HAV) and Patients with Acute Hepatitis E Virus (HEV): A Single-Center Retrospective Study from Bulgaria.Infection and drug resistance · 2023Article
- Seroprevalence of Anti-Hepatitis E Virus Antibodies among Patients from a Tertiary Hospital from Northeast Romania.Medicina (Kaunas, Lithuania) · 2022Article
- Article
- Detection of hepatitis E virus RNA from pig bile collected at a slaughterhouse in Japan.AIMS microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral hepatitis A to E describes various infectious inflammations of the liver parenchyma that are caused by the hepatitis viruses A to E (HAV, HBV, HCV, HDV, and HEV). Although the clinical pictures are similar, the pathogens belong to different virus families and differ in terms of pathogenesis, transmission routes, clinical course, prevention, and therapy options. In Germany, there is mandatory reporting according to the Infection Protection Act (IfSG) for direct or indirect laboratory evidence and for suspicion, illness, and death of viral hepatitis. The data are transmitted to the Robert Koch Institute.In this article, on the basis of published studies and notification data, we describe the epidemiology of hepatitis A to E as well as current challenges and prevention approaches. In particular, the latter contains the improvement of existing vaccination recommendations (hepatitis A and B); improvement of access to prevention, testing, and care including therapy with antiviral drugs (hepatitis B, C, and D) and the detection and prevention of foodborne infections and outbreaks; and improvements in the field of food safety (hepatitis A and E).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.